Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

463
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
463
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

714
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
714
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

424
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
424
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

466
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
466
Analgesia and Pain Management01:25

Analgesia and Pain Management

1.1K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.1K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

653
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
653

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The divided dose approach to perioperative buprenorphine -management in patients with opioid use disorder.

Journal of opioid management·2021
Same author

Rectus Sheath Hematoma Associated with Apixaban.

Clinics and practice·2017
Same author

Author Reply.

Pharmacotherapy·2016
Same author

Possible Rivaroxaban Failure during the Postpartum Period: An Alternative Viewpoint.

Pharmacotherapy·2016
Same author

Increasing Hospital Pharmacist Clinical Competence in Intensive Pharmacotherapeutics Using a Novel Pharmacist Clinical Educational Program.

Hospital pharmacy·2016
Same author

Possible Rivaroxaban Failure during the Postpartum Period.

Pharmacotherapy·2015
Same journal

Systemic Amyloidosis: A Clinical Challenge from the Palliative Care Perspective.

Journal of pain & palliative care pharmacotherapy·2026
Same journal

Cancer Patients with Neuropathic Pain: Pharmacist-Led Recommendation and Management and Mirogabalin Outcomes in a Single-Center Retrospective Observational Cohort.

Journal of pain & palliative care pharmacotherapy·2026
Same journal

Cost-Effectiveness of Integrative Pain Management for Chronic Pain: A Systematic Review of Economic Evaluation.

Journal of pain & palliative care pharmacotherapy·2026
Same journal

High-Dose Monotherapy or Combination Therapy in Neuropathic Pain: A Necessary Reflection.

Journal of pain & palliative care pharmacotherapy·2026
Same journal

The Price of Goodbye.

Journal of pain & palliative care pharmacotherapy·2026
Same journal

In the End, What Shall We Say?

Journal of pain & palliative care pharmacotherapy·2026
See all related articles

Related Experiment Video

Updated: Nov 17, 2025

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
03:50

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

2.4K

Rethinking Docusate's Role in Opioid-Induced Constipation: A Critical Analysis of the Evidence.

Amanda L Engle, Amanda R McFee Winans

    Journal of Pain & Palliative Care Pharmacotherapy
    |February 17, 2021
    PubMed
    Summary
    This summary is machine-generated.

    Docusate is widely recommended for opioid-induced constipation (OIC) but lacks strong clinical evidence. Healthcare providers should review OIC protocols to ensure evidence-based treatments and reduce unnecessary drug use.

    Keywords:
    Docusateopioid induced constipationprophylaxisstool softenertreatment

    More Related Videos

    Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
    04:04

    Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

    Published on: July 5, 2024

    736
    Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
    12:37

    Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS

    Published on: September 11, 2012

    47.5K

    Related Experiment Videos

    Last Updated: Nov 17, 2025

    Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
    03:50

    Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

    Published on: August 18, 2023

    2.4K
    Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
    04:04

    Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

    Published on: July 5, 2024

    736
    Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
    12:37

    Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS

    Published on: September 11, 2012

    47.5K

    Area of Science:

    • Gastroenterology
    • Pharmacology
    • Evidence-Based Medicine

    Background:

    • Opioid-induced constipation (OIC) is a common adverse effect of opioid therapy.
    • Docusate is frequently used for OIC prophylaxis and treatment due to its availability and low cost.
    • Concerns exist regarding docusate's limited efficacy despite its widespread recommendation.

    Purpose of the Study:

    • To critically review the clinical evidence supporting the use of docusate in managing OIC.
    • To evaluate the basis for docusate's inclusion in clinical guidelines and consensus recommendations for OIC.

    Main Methods:

    • A comprehensive literature search was conducted across PubMed, Google Scholar, OVID Medline, and EMBASE.
    • The review included primary literature, clinical guidelines, and consensus recommendations (CR) related to docusate for OIC.
    • Thirteen guidelines/CR and four primary studies were analyzed.

    Main Results:

    • Primary literature studies evaluating docusate for OIC exhibited significant design limitations and provided weak evidence.
    • Most guidelines and CR recommending docusate for OIC did not cite supporting primary research.
    • Docusate's inclusion in major OIC guidelines is based on limited evidence, yet its use remains prevalent.

    Conclusions:

    • The evidence base for docusate in OIC management is weak.
    • Healthcare institutions should reassess OIC protocols to prioritize evidence-based therapies.
    • Consideration should be given to removing docusate from OIC management to reduce unnecessary drug use and costs.